Lophius Biosciences GmbH Joins NEU²
Hamburg/Regensburg, Germany, June 19, 2013 / B3C newswire / - Bionamics GmbH, the coordinator of the NEU² consortium,and Lophius Biosciences GmbH announced today that Lophius Biosciences has joined the NEU² program with a project addressing the development of T-Track® MS as a novel blood-based diagnostic test supporting the initial diagnosis of multiple sclerosis (MS) and enabling the monitoring of MS disease progression. This new project is to last for about two years with a funding of > 350.000 EUR proportionally supplied by The Federal Ministry of Education and Research (BMBF) under the BioPharma initiative.
Mehr unter http://www.bio-m.org/pressemitteilungen/details/3299.html
Führender Standort für rote Biotechnologie Der Großraum München ist der führende biopharmazeutische Standort in Deutschland. Die Mehrza...
[mehr]